Search Results

Filter
  • 1-10 of  26 results for ""Liver-Specific Organic Anion Transporter 1""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Enantiospecific Pharmacogenomics of Fluvastatin.

  • Authors : Hirvensalo P; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.

Subjects: Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*chemistry ; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*pharmacokinetics ; Cytochrome P-450 CYP2C9/Cytochrome P-450 CYP2C9/Cytochrome P-450 CYP2C9/*genetics

  • Source: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2019 Sep; Vol. 106 (3), pp. 668-680. Date of Electronic Publication: 2019 May 14.Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535

Record details

×
Academic Journal

Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.

  • Authors : Wu HF; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California 94143.; Hristeva N

Subjects: Polymorphism, Single Nucleotide*; ATP Binding Cassette Transporter, Subfamily G, Member 2/ATP Binding Cassette Transporter, Subfamily G, Member 2/ATP Binding Cassette Transporter, Subfamily G, Member 2/*genetics ; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*blood

  • Source: Journal of pharmaceutical sciences [J Pharm Sci] 2017 Sep; Vol. 106 (9), pp. 2751-2757. Date of Electronic Publication: 2017 Apr 03.Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.

Subjects: Drug Interactions*; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*pharmacokinetics ; Atorvastatin/Atorvastatin/Atorvastatin/*pharmacokinetics

  • Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 Nov; Vol. 10 (11), pp. 1335-1344. Date of Electronic Publication: 2021 Jun 09.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.

  • Authors : Lee N; Sugiyama Laboratory, RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan; Life Science Research Institute, Daewoong Pharmaceutical, Co., Ltd., 72 Dugye-ro, Pogok-eup, Cheoin-gu, Yongin, 17028, South Korea.

Subjects: Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*pharmacokinetics ; Atorvastatin/Atorvastatin/Atorvastatin/*pharmacokinetics ; Hypercholesterolemia/Hypercholesterolemia/Hypercholesterolemia/*drug therapy

  • Source: Drug metabolism and pharmacokinetics [Drug Metab Pharmacokinet] 2019 Dec; Vol. 34 (6), pp. 387-395. Date of Electronic Publication: 2019 Aug 29.Publisher: Elsevier Country of Publication: England NLM ID: 101164773 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1880-0920

Record details

×
Academic Journal

Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease.

  • Authors : Tirona RG; Department of Physiology and Pharmacology (R.G.T., C.Z., U.I.S, R.B.K.), Division of Clinical Pharmacology, Department of Medicine (R.G.T., C.Z., M.L., U.I.S., R.B.K.), Department of Medical Imaging (Z.K.), Division of Gastroenterology, Department of Medicine (B.A.-J., M.D.B.), and Lawson Health Research Institute (R.G.T., Z.K., R.S., M.R., U.I.S., R.B.K., M.D.B.), University of Western Ontario, London, Ontario, Canada; and Department of Medicine, University of Rochester, Rochester, New York (B.A.-J.).

Subjects: Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*pharmacokinetics ; Factor Xa Inhibitors/Factor Xa Inhibitors/Factor Xa Inhibitors/*pharmacokinetics ; Non-alcoholic Fatty Liver Disease/Non-alcoholic Fatty Liver Disease/Non-alcoholic Fatty Liver Disease/*metabolism

  • Source: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2018 May; Vol. 46 (5), pp. 485-492. Date of Electronic Publication: 2018 Feb 22.Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model:

Record details

×
Academic Journal

The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.

  • Authors : de Keyser CE; Departments of aEpidemiology bInternal Medicine, Erasmus Medical Center, Rotterdam cDrug Safety Unit, The Health Care Inspectorate dDepartment of Hospital Pharmacy, Pharmacy Foundation of The Hague Hospitals - HAGA eNetherlands Consortium of Healthy Aging, The Hague fDepartment of Pharmacoepidemiology & Clinical Pharmacotherapy, Utrecht University, Utrecht gDepartment of Clinical Pharmacy, St Antonius Hospital Nieuwegein, Nieuwegein hDepartment of Hospital Pharmacy, Pharmacy Foundation of Haarlem Hospitals, Haarlem, The Netherlands iDepartment of Molecular Genetics, Pharmacogenetics and Hormone Research, Bicêtre Hospital, Paris, France.; Peters BJ

Subjects: Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*therapeutic use ; Heptanoic Acids/Heptanoic Acids/Heptanoic Acids/*therapeutic use ; Hypercholesterolemia/Hypercholesterolemia/Hypercholesterolemia/*drug therapy

  • Source: Pharmacogenetics and genomics [Pharmacogenet Genomics] 2014 Jan; Vol. 24 (1), pp. 43-51.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101231005 Publication Model: Print Cited Medium: Internet

Record details

×
Academic Journal

Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.

  • Authors : Shabana MF; Department of Pharmacology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.; Mishriki AA

Subjects: ATP Binding Cassette Transporter, Subfamily B, Member 1/ATP Binding Cassette Transporter, Subfamily B, Member 1/ATP Binding Cassette Transporter, Subfamily B, Member 1/*genetics ; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*therapeutic use ; Heptanoic Acids/Heptanoic Acids/Heptanoic Acids/*therapeutic use

  • Source: Molecular diagnosis & therapy [Mol Diagn Ther] 2013 Oct; Vol. 17 (5), pp. 299-309.Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 101264260 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia.

  • Authors : Sorich MJ; School of Pharmacy and Medical Sciences and Sansom Institute for Health Research, University of South Australia, GPO Box 2471, Adelaide, SA, 5001, Australia. ; Wiese MD

Subjects: Pharmacogenetics*; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*therapeutic use ; Hypercholesterolemia/Hypercholesterolemia/Hypercholesterolemia/*drug therapy

  • Source: PharmacoEconomics [Pharmacoeconomics] 2013 May; Vol. 31 (5), pp. 377-91.Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9212404 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia.

  • Authors : Hu M; Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR.; Mak VW

Subjects: Genetic Variation* ; Introns*; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*therapeutic use

  • Source: Pharmacogenetics and genomics [Pharmacogenet Genomics] 2012 Nov; Vol. 22 (11), pp. 803-6.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101231005 Publication Model: Print Cited Medium: Internet

Record details

×
Academic Journal

SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.

  • Authors : Sortica VA; Departamento de Genética, Universidade Federal do RioGrande do Sul, Porto Alegre, Brazil.; Fiegenbaum M

Subjects: Polymorphism, Single Nucleotide*; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*pharmacology ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/Hydroxymethylglutaryl-CoA Reductase Inhibitors/Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology

  • Source: Clinical chemistry and laboratory medicine [Clin Chem Lab Med] 2012 Mar; Vol. 50 (3), pp. 441-8.Publisher: Walter De Gruyter Country of Publication: Germany NLM ID: 9806306 Publication Model: Print Cited Medium: Internet ISSN: 1437-4331

Record details

×
  • 1-10 of  26 results for ""Liver-Specific Organic Anion Transporter 1""